12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oncotype DX prostate cancer assay diagnostic data

Genomic Health and researchers at the University of California, San Francisco, reported top-line data from a clinical validation study in patients with early stage prostate cancer showing that the Oncotype DX Genomic Prostate Score (GPS) met the primary endpoint by prospectively predicting adverse pathology from prostate needle biopsy tumor tissue...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >